Andrew Berens
Stock Analyst at Leerink Partners
(2.28)
# 2,615
Out of 5,124 analysts
96
Total ratings
47.78%
Success rate
-3.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $27.47 | +45.61% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $97.12 | +53.42% | 3 | Nov 17, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $50 | $34.78 | +43.76% | 6 | Nov 10, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $6.72 | +123.21% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $11.59 | +115.70% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $105.02 | -42.87% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $11.83 | -23.92% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $4.91 | +22.20% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $776.54 | -1.87% | 1 | Jan 28, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.78 | +1,087.05% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $24.18 | +3.39% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $121.36 | -20.90% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $106.66 | -26.87% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $17.43 | +60.64% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $94.96 | -16.81% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.78 | +1,416.85% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $10.16 | +146.06% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.16 | +675.19% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.03 | +3,200.49% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $16.01 | +24.92% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.67 | +158.53% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $11.25 | -28.89% | 7 | Jul 14, 2017 |
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $27.47
Upside: +45.61%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $97.12
Upside: +53.42%
Cogent Biosciences
Nov 10, 2025
Maintains: Outperform
Price Target: $18 → $50
Current: $34.78
Upside: +43.76%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $6.72
Upside: +123.21%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $11.59
Upside: +115.70%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $105.02
Upside: -42.87%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $11.83
Upside: -23.92%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $4.91
Upside: +22.20%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $776.54
Upside: -1.87%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.78
Upside: +1,087.05%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $24.18
Upside: +3.39%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $121.36
Upside: -20.90%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $106.66
Upside: -26.87%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $17.43
Upside: +60.64%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $94.96
Upside: -16.81%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.78
Upside: +1,416.85%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $10.16
Upside: +146.06%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.16
Upside: +675.19%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.03
Upside: +3,200.49%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $16.01
Upside: +24.92%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $9.67
Upside: +158.53%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $11.25
Upside: -28.89%